Effect of tramadol administered at different time on postoperative shivering and patients' satisfactory.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000385

Enrollment

Unknown

Registered

2009-04-30

Start date

2009-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative shivering

Interventions

Group A:administered tramadol 1.5mg/kg after induction

Group B:administered tramadol 1.5mg/kg before skin closure

Group C:Saline placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18~65yr, ASA I-II, elective abdominal surgery of about 2~4h.

Exclusion criteria

Exclusion criteria: Exclusion criteria: BMI>30kg/m2, fever (temperature>37.8 degree C), pre- or peri-operative treatment with vasoactive, psychiatric or analgesic drugs, alcohol or drug dependence, heart failure,liver or kidney dysfunction, muscle diseases, symptoms or signs of Parkinson's disease and other neurological or psychiatric disorders, hypersensitivity to tramadol and pregnancy.

Design outcomes

Primary

Measure	Time frame
shivering occurrence rate;	—

Secondary

Measure	Time frame
vital sign(BP, HR, T, SPO2), PONV and other adverse effect, sedation, pain and satisfactory score.;	—

Countries

China

Contacts

Public ContactLiu Jin

liujin123@163.com+86 028 81812539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026